TCGA-AR-A256-01A-11R-A169-07
— · E
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- E
- subtype
- E
- overall_survival_months
- 95
- os_event
- true
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.570
- E2F_TARGETS+0.560
- MYC_TARGETS_V1+0.550
- G2M_CHECKPOINT+0.530
- MITOTIC_SPINDLE+0.390
- OXIDATIVE_PHOSPHORYLATION+0.290
- TNFA_SIGNALING_VIA_NFKB+0.290
- INFLAMMATORY_RESPONSE+0.260
- NOTCH_SIGNALING+0.260
- SPERMATOGENESIS+0.240
Top 10 suppressed
- ESTROGEN_RESPONSE_LATE-0.350
- ESTROGEN_RESPONSE_EARLY-0.330
- MYOGENESIS-0.300
- COAGULATION-0.260
- XENOBIOTIC_METABOLISM-0.230
- BILE_ACID_METABOLISM-0.210
- INTERFERON_ALPHA_RESPONSE-0.190
- P53_PATHWAY-0.190
- APOPTOSIS-0.150
- PEROXISOME-0.110
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-A8-A07O-01A-11R-A00Z-07 | — | E | 0.858 |
| 2 | TCGA-BH-A18T-01A-11R-A12D-07 | — | E | 0.826 |
| 3 | de5a4588-05ec-461f-9235-90611b01f4b6 | — | — | 0.814 |
| 4 | TCGA-AN-A0AT-01A-11R-A034-07 | — | E | 0.805 |
| 5 | SRR8613795 | — | E | 0.788 |
| 6 | TCGA-C8-A1HJ-01A-11R-A13Q-07 | — | E | 0.778 |
| 7 | TCGA-B6-A0RE-01A-11R-A056-07 | — | E | 0.777 |
| 8 | TCGA-AN-A0G0-01A-11R-A034-07 | — | E | 0.773 |
| 9 | SRR12475133 | — | — | 0.770 |
| 10 | SRR1313139 | — | E | 0.767 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.570 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.560 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.550 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.530 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.390 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.290 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.290 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.260 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.260 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.240 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.230 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.230 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.190 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.160 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.120 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.100 | Idelalisib | — uncovered |
| HYPOXIA | 0.100 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.050 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.040 | Temsirolimus | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.040 | Inavolisib | — uncovered |